
    
      FGF-1 administered by intramuscular injection for the treatment of peripheral arterial
      disease with intermittent claudication. Eligible patients are allocated to one of three
      treatment arms. Patients within each dosing group will be randomized between study drug and
      vehicle control. Safety, pharmacokinetics, and cardiovascular improvement will be evaluated
      at day 1 and weeks 1, 4 and 12 post dosing.
    
  